-
Adakveo Approved by EU for Pain Crises in SCD Patients, 16 and Older
Adakveo is now approved in the European Union as a preventive treatment for recurrent vaso-occlusive crises in sickle cell disease patients, 16 and older. Read the full story here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.